List of APIs/Active Pharmaceutical Ingredients Companies in Netherlands - 3

Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs). We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 1,800 employees work continuously to meet our customers' needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek', our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm.

InnoCore specializes in the formulation, process development, and manufacturing of long acting and minimally invasive injectable drug delivery products. InnoCore offers a unique and highly tunable polymer platform to control the delivery drug compounds, including small molecules (e.g. peptides and low solubles) and biologics (e.g. proteins and antibodies). Our proprietary polymer platform features a variety of benefits to your API's such as: - solving toxicity challenges - maintaining/increasing stability and structural integrity of sensitive compounds (e.g. by applying low temperature process conditions during manufacturing) - sustained release of of drug molecules from days up to at least 6 months - precise control over particle size (preventing absorption by macrophages and ensuring injectability) - ensuring smooth bioavailability - enabling the use of small needle sizes for patient compliance By merging developmental collaborations and licensing partnerships with our exclusive SynBiosys biodegradable polymer technologies, we generate innovative injectable and implantable drug delivery products. We invite you to navigate through our website and discover how we can enhance the performance of your device and/or drug and add value to your product pipeline.

Pantarhei Bioscience BV (PRB) is a company in The Netherlands with an innovative concept of drug development in Woman’s Health. PRB's wholly owned subsidiary company – Pantarhei Oncology (PRO) (http://www.pantarheioncology.nl) develops innovative treatments for Endocrine Cancer. PRB and PRO have developed a product pipeline based on the proven ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals and combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments such as contraception and menopausal hormone therapy (MHT). The main areas of expertise of PRO are and in oncology breast cancer, prostate cancer and ovarian cancer. The business concept of PRB and PRO is to develop the patented new treatment concepts up to proof-of-concept (PoC) in the human (phase II). Using existing molecules often provides first evidence of safety. The business model is based on solid patent protection, internal project management and external research and development activities. Intellectual property (IP) and data supporting the new treatment concepts are licensed out for completion of clinical development (phase III), regulatory approval and sales and marketing by a licensee/partner.